Diabetes patients on dulaglutide (Trulicity) had better glycemic control and more weight loss if they switched to tirzepatide ...

The study finds better A1c lowering and weight reduction, but an expert clinician says practical issues may pose barriers.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs ...

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Citi analyst Daniel Grosslight says Hims & Hers traded up 10% yesterday after Bloomberg noted the company is now offering branded ...

Tirzepatide has been shown to help people lose more weight compared to semaglutide at the dosage regimens currently available ...

Findings from the SUMMIT, Altshock-2, and FAIR-HF2 trials were presented at the American College of Cardiology 2025 Annual ...

In patients with heart failure with preserved ejection fraction and obesity, tirzepatide improved clinical outcomes compared ...

For patients with inadequately controlled type 2 diabetes receiving dulaglutide, switching to tirzepatide is associated with additional hemoglobin A1c (HbA1c) reduction and weight loss compared with ...